FDA Patient Listening Session for Non-Small Cell Lung Cancer
1 Views
administrator
07/14/23
FDA Patient Listening Session "Drug Development in Molecular Subsets of Non-Small Cell Lung Cancer – Challenges and Opportunities from a Patient Perspective". - The session generated significant insight into the challenges regarding Targeted Therapy Clinical Trials, Survivorship and Quality of Life and access to Biomarker Testing.
-
Category
Show more
Facebook Comments
No comments found